CN113194955A - 新用途 - Google Patents

新用途 Download PDF

Info

Publication number
CN113194955A
CN113194955A CN201980084405.9A CN201980084405A CN113194955A CN 113194955 A CN113194955 A CN 113194955A CN 201980084405 A CN201980084405 A CN 201980084405A CN 113194955 A CN113194955 A CN 113194955A
Authority
CN
China
Prior art keywords
alkyl
pde1 inhibitor
phenyl
independently
replacement therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980084405.9A
Other languages
English (en)
Chinese (zh)
Inventor
R·E·戴维斯
K·E·瓦诺维尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intra Cellular Therapies Inc
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of CN113194955A publication Critical patent/CN113194955A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980084405.9A 2018-10-21 2019-10-21 新用途 Pending CN113194955A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862748517P 2018-10-21 2018-10-21
US62/748,517 2018-10-21
PCT/US2019/057260 WO2020086481A1 (en) 2018-10-21 2019-10-21 Novel uses

Publications (1)

Publication Number Publication Date
CN113194955A true CN113194955A (zh) 2021-07-30

Family

ID=70331921

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980084405.9A Pending CN113194955A (zh) 2018-10-21 2019-10-21 新用途

Country Status (11)

Country Link
US (2) US12194042B2 (https=)
EP (1) EP3866808A4 (https=)
JP (1) JP7480135B2 (https=)
KR (1) KR20210080418A (https=)
CN (1) CN113194955A (https=)
AU (1) AU2019364274C1 (https=)
BR (1) BR112021007571A2 (https=)
CA (1) CA3117148A1 (https=)
IL (1) IL282396A (https=)
MX (1) MX2021004531A (https=)
WO (1) WO2020086481A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020210614A1 (en) * 2019-04-12 2020-10-15 Intra-Cellular Therapies, Inc. Organic compounds
EP4413980A3 (en) 2019-09-03 2024-10-30 Intra-Cellular Therapies, Inc. Novel compounds
MX2023008755A (es) * 2021-01-27 2023-08-02 Intra Cellular Therapies Inc Cristales de sal.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101970444A (zh) * 2007-12-06 2011-02-09 细胞内治疗公司 有机化合物
WO2018069312A1 (en) * 2016-10-11 2018-04-19 Deutsches Zentrum Für Neurodegenerative Erkrankungen E. V. (Dzne) Treatment of synucleinopathies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2465893A1 (en) * 2001-11-09 2003-05-22 Schering Corporation Polycyclic guanine derivative phosphodiesterase v inhibitors
RS52166B (sr) 2007-05-11 2012-08-31 Pfizer Inc. Amino-heterociklična jedinjenja
WO2010098839A1 (en) 2009-02-25 2010-09-02 Intra-Cellular Therapies, Inc. Pde 1 inhibitors for ophthalmic disorders
TW201206937A (en) * 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
CA2961212C (en) 2014-09-17 2024-02-06 Intra-Cellular Therapies, Inc. Compounds and methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101970444A (zh) * 2007-12-06 2011-02-09 细胞内治疗公司 有机化合物
WO2018069312A1 (en) * 2016-10-11 2018-04-19 Deutsches Zentrum Für Neurodegenerative Erkrankungen E. V. (Dzne) Treatment of synucleinopathies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
INTRA-CELLULAR THERAPIES: "Intra-Cellular Therapies Presents Data on ITI-214 at the 2018 American Academy of Neurology Annual Meeting", 《网络公开INTRA-CELLULAR THERAPIES INC.》, pages 1 - 2 *
PENG LI等: ""Discovery of Potent and Selective Inhibitors of Phosphodiesterase 1 for the Treatment of Cognitive Impairment Associated with Neurodegenerative and Neuropsychiatric Diseases", 《JOURNAL OF MEDICINAL CHEMISTRY》, vol. 59, no. 3, pages 1 - 52 *

Also Published As

Publication number Publication date
US12194042B2 (en) 2025-01-14
US20250090536A1 (en) 2025-03-20
AU2019364274A1 (en) 2021-06-03
EP3866808A4 (en) 2023-04-12
US20210379072A1 (en) 2021-12-09
BR112021007571A2 (pt) 2021-07-27
CA3117148A1 (en) 2020-04-30
AU2019364274C1 (en) 2025-04-10
EP3866808A1 (en) 2021-08-25
IL282396A (en) 2021-06-30
KR20210080418A (ko) 2021-06-30
AU2019364274B2 (en) 2024-10-17
JP7480135B2 (ja) 2024-05-09
JP2022505471A (ja) 2022-01-14
WO2020086481A1 (en) 2020-04-30
MX2021004531A (es) 2021-09-10

Similar Documents

Publication Publication Date Title
JP7579888B2 (ja) 治療用固形製剤
US20250090536A1 (en) Uses
JP2025125557A (ja) 心理療法を補助するためのｍｄｍａプロドラッグ
JP6696904B2 (ja) 製剤および医薬組成物
US6458791B1 (en) Methods of treating muscle spasms using N-desmethylzopiclone
US20120028991A1 (en) Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands
JP7749896B2 (ja) 気分障害のための新規ガンマアミノ酪酸型受容体モジュレーター
Giardina et al. Adrogolide HCl (ABT‐431; DAS‐431), a prodrug of the dopamine D1 receptor agonist, A‐86929: preclinical pharmacology and clinical data
EP2624821B1 (en) Combination therapy for the treatment of depression and other non-infectious diseases
US20140271890A1 (en) Controlled-release pharmaceutical composition
KR101408650B1 (ko) 무스카린성 수용체 ｍ1 길항제를 이용한 심리 질환 치료 방법
WO2021191417A1 (en) Compounds for use in the treatment of synucleinopathies
HK40057178A (en) Novel uses
RU2836384C2 (ru) Новые применения
WO1993010787A1 (en) Methods and compositions for treating sleep disorders, convulsive seizures, and other disorders using optically pure (+) zopiclone
CN101472571A (zh) 使用毒蕈碱型受体m1拮抗剂治疗心理学病况
JPH09500375A (ja) パーキンソン病の治療を目的とする医薬品の製造のためのエファロキサンおよびその誘導体の使用
KR20090031908A (ko) Ｓｌｖ308 및 ｌ-ｄｏｐａ를 포함하는 병용 제제
JP2025160326A (ja) 処置方法
WO1993010788A1 (en) Methods and compositions for treating sleep disorders, convulsive seizures, and other disorders using optically pure (-) zopiclone

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40057178

Country of ref document: HK